Published in Ann Clin Biochem on July 01, 2004
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
Inborn errors of purine and pyrimidine metabolism. J Inherit Metab Dis (2009) 1.06
Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol (2006) 0.90
Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol (2015) 0.88
Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients. Dig Dis Sci (2012) 0.81
Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis (2015) 0.78
Do ITPA and TPMT genotypes predict the development of side effects to AZA? Gut (2006) 0.77
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. Br J Clin Pharmacol (2006) 0.76
Thiopurine methyltransferase screening before azathioprine therapy. Br J Ophthalmol (2006) 0.76
Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics (2016) 0.75
The drugs don't work: pharmacogenomics--clinical biochemistry's future? Ann Clin Biochem (2004) 0.75
6-Mercaptopurine Modifies Cerebrospinal Fluid T-cell Abnormalities in Pediatric Opsoclonus-Myoclonus as Steroid Sparer. Clin Exp Immunol (2017) 0.75
Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics (2004) 2.04
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet (2002) 2.03
The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta (2006) 1.28
PRPS1 mutations: four distinct syndromes and potential treatment. Am J Hum Genet (2010) 1.26
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Phosphoribosylpyrophosphate synthetase superactivity and recurrent infections is caused by a p.Val142Leu mutation in PRS-I. Am J Med Genet A (2012) 0.96
Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol (2004) 0.87
Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem (2005) 0.87
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis (2010) 0.86
Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics (2003) 0.83
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health (2011) 0.82
Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. Inflamm Bowel Dis (2014) 0.80
Aqueous normal phase retention of nucleotides on silica hydride-based columns: method development strategies for analytes relevant in clinical analysis. J Sep Sci (2010) 0.78
Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. Inflamm Bowel Dis (2016) 0.77
Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone. Inflamm Bowel Dis (2017) 0.75
Simultaneous determination of thymine and its sequential catabolites dihydrothymine and β-ureidoisobutyrate in human plasma and urine using liquid chromatography-tandem mass spectrometry with pharmacokinetic application. J Pharm Biomed Anal (2013) 0.75